Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

myneuronews September 13, 2021

0 Comments

The US Food and Drug Administration (FDA) approved aducanumab on June 7, 2021, using an accelerated approval mechanism, based on evidence that aducanumab reduced brain β-amyloid (Aβ) peptide.¹ The FDA press release stated that the effect on the surrogate end point “is reasonably likely to predict a clinical benefit to patients…” at some point in the future. As clinical neurologists, we should understand the evidence for this approval and whether this justifies prescribing this medication.

Read article at journal's website

Categories: General Neurology

The Prehospital Stroke Score and telephone conference: A prospective validation

Abstract Objectives The main aim of the study is to investigate the performance of a two-part stroke scale for screening and subsequent severity assessment combined…

myneuronews January 13, 2022

0 Comments

Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

Background and Objectives Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and…

myneuronews March 1, 2022

0 Comments

Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?

We recently learned that aducanumab has been approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer disease. As neurologists, we…

myneuronews September 13, 2021

0 Comments

Practical Considerations in the Administration of Aducanumab for the Neurologist

Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration…

myneuronews April 13, 2022

0 Comments

Discovery and Development of Pregabalin (Lyrica): The Role of Public Funding

Background and Objectives Pregabalin (Lyrica), a widely used drug that has generated billions in revenue as a treatment for diabetic neuropathy and other conditions, was…

myneuronews October 26, 2021

0 Comments

Related Articles

Responses